

Oliver FloÃmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/467260/publications.pdf>

Version: 2024-02-01

32
papers

3,284
citations

304743

22
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

2348
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.9	719
2	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	27.0	465
3	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.9	348
4	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 542-548.	6.7	298
5	Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. <i>Kidney International</i> , 2013, 84, 397-402.	5.2	220
6	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.9	214
7	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	3.4	147
8	Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3472-3477.	6.7	117
9	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	1.9	104
10	Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. <i>Blood</i> , 2016, 128, 2824-2833.	1.4	97
11	The characterisation and determinants of quality of life in ANCA associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 207-211.	0.9	74
12	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1571-1576.	4.5	53
13	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	3.5	42
14	Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1084-1091.	6.1	42
15	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	1.9	42
16	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 953-956.	1.9	38
17	Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. <i>Kidney International</i> , 2021, 99, 227-237.	5.2	33
18	Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. <i>Rheumatology</i> , 2010, 49, 556-562.	1.9	31

#	ARTICLE	IF	CITATIONS
19	Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. <i>Rheumatology</i> , 2017, 56, 1894-1901.	1.9	31
20	The long-term outcomes of systemic vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i60-6.	0.7	29
21	Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. <i>Rheumatology</i> , 2015, 54, 899-907.	1.9	29
22	Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis. <i>Presse Medicale</i> , 2015, 44, e251-e257.	1.9	28
23	Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. <i>Rheumatology</i> , 2019, 58, 103-109.	1.9	24
24	ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. <i>PLoS ONE</i> , 2016, 11, e0165402.	2.5	21
25	Gusperimus: immunological mechanism and clinical applications. <i>Rheumatology</i> , 2014, 53, 1732-1741.	1.9	13
26	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. <i>Kidney360</i> , 2022, 3, 293-306.	2.1	10
27	Maintaining remission in a patient with vasculitis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 499-504.	3.2	5
28	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelinesâ€”Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	1.9	5
29	Evolution of biological agents: how established drugs can become less safe. <i>BMJ: British Medical Journal</i> , 2017, 357, j1707.	2.3	4
30	Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report. <i>BMC Nephrology</i> , 2020, 21, 175.	1.8	1
31	301.â€fLOW GRADE RENAL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
32	Case of the month from the Department of Urology, Oxford University Hospitals, Oxford, UK: open partial nephrectomy of a transplant kidney in a patient with Fabryâ€™s disease. <i>BJU International</i> , 2022, 129, 164-167.	2.5	0